Cholera vaccines

Clinical Infectious Diseases

Volumn 31, Issue 2, 2000, Pages 561-565

  Ryan, Edward T ^a   Calderwood, Stephen B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHLOROQUINE; CHOLERA VACCINE; INACTIVATED VACCINE; LIVE VACCINE; MEFLOQUINE; PHENOL; TYPHOID VACCINE;

ABDOMINAL DISEASE; ARTICLE; CHOLERA; CLINICAL TRIAL; DRUG EFFICACY; ERYTHEMA; FEVER; HEADACHE; HUMAN; MALAISE; PRIORITY JOURNAL; REHYDRATION; VIBRIO CHOLERAE;

CHOLERA; CHOLERA TOXIN; CHOLERA VACCINES; HUMANS; IMMUNIZATION SCHEDULE; TRAVEL; VACCINES, ATTENUATED; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIBRIO CHOLERAE;

EID: 0034456387     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313951     Document Type: Article

References (38)

1. Mortality, morbidity and microbiology of endemic cholera in Dhaka, Bangladesh
2. Risk of cholera among Western and Japanese travelers
3. Cholera associated with an international airline flight, 1992
4. Summary of notifiable diseases, United States, 1998
5. Cholera
6. Cholera among Americans living in Peru
7. Health problems after travel to developing countries
8. Immunity and vaccine development
9. Recombinant live cholera vaccines
10. Protective oral cholera vaccine based on a combination of cholera toxin B subunit and inactivated cholera vibrios
11. Field trial of oral cholera vaccines in Bangladesh
12. Field trial of oral cholera vaccines in Bangladesh: Results from a three-year follow-up
13. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: Results of a large-scale field trial
14. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine
15. Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera
16. Immunogenicity in Peruvian volunteers of a booster dose of oral cholera vaccine consisting of whole cells plus recombinant B subunit
17. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits
18. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR
19. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults
20. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: Results of a randomized, placebo-controlled, double-blind crossover trial
21. Live oral vaccines against cholera: An update
22. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR
23. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor inaba three months after vaccination
24. Factors influencing secondary vibriocidal immune responses: Relevance for understanding immunity to cholera
25. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area
26. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mall
27. Local and systemic immune responses to combined Vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a live oral vaccines after primary immunization and reimmunization
28. CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor
29. Development of a live, oral, attenuated vaccine against El Tor cholera
30. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1
31. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype
32. Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama
33. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine
34. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam
35. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers
36. In vivo expression and immunoadjuvancyof a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae
37. Development of a ΔglnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae
38. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholera O1 El tor inaba 3 months after vaccination